BRP Inc. (TSX:DOO) shares fell 6.47% on September 8th despite a positive quarterly update, indicating profit-taking, valuation reassessment, and concerns over tariffs and inflation. The company's business model relies on powersports and marine product sales, but its discretionary nature makes it susceptible to economic uncertainties. Key risks include trade policy, consumer cyclicality, competitive pressures, and geopolitical instability.

Editas Medicine is preparing to initiate the first human trial in Australia for EDIT-401, a CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The therapy, delivered via a single intravenous infusion, has shown promising results in non-human primates, significantly reducing LDL cholesterol and increasing LDL receptor expression. The company expects to share human safety data in Q1 2027 and initial efficacy results later that year, with sufficient cash reserves to fund development into the second half of 2028.

Capital Advantage Inc. reduced its stake in Advanced Micro Devices (AMD) by 23.7% in the second quarter, selling 5,783 shares but still holding 18,668 shares worth approximately $10.8 million. AMD exceeded Q2 analyst expectations with $1.66 EPS and $11.54 billion in revenue, reflecting 50.1% year-over-year growth. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $557.62, while institutional investors own a significant 71.34% of the company.

C WorldWide Group Holding A S acquired a new stake in First Solar, Inc. (NASDAQ:FSLR) by purchasing 31,495 shares worth approximately $7.4 million in the second quarter. Other institutional investors also significantly increased their holdings, with First Solar's stock now 92.08% owned by institutional investors and hedge funds. The company recently reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with an average price target of $266.27 from analysts.

Cidel Asset Management Inc. increased its stake in Darden Restaurants (NYSE:DRI) by 57.7% in the second quarter, purchasing 23,502 shares to own a total of 64,239 shares valued at approximately $13.2 million. Darden Restaurants recently reported strong quarterly earnings, beating analyst estimates, and raised its quarterly dividend. Analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $230.50.

Teamwork Financial Advisors LLC significantly reduced its stake in Emerson Electric Co. (NYSE:EMR) by 93% in the second quarter, selling 24,791 shares and retaining 1,874 shares worth $268,000. Despite this, institutional investors collectively own 74.3% of EMR, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $167.83. Emerson Electric also reported strong quarterly results, surpassing EPS and revenue expectations, and declared a quarterly dividend of $0.555 per share.

Bristol Myers Squibb's CAR T therapy, arlocabtagene autoleucel (arlo-cel), showed significant improvements in response rates during a mid-stage study for relapsed and refractory multiple myeloma. Analysts believe this positions arlo-cel to treat a distinct patient population, specifically those exposed to four prior lines of treatment, reducing direct competition with Gilead Sciences' upcoming CAR T therapy, anito-cel. The positive results are seen as a "key derisking event" for BMS, despite recent safety concerns with another one of its investigational CAR T medicines.

Applebee's is celebrating National Cheeseburger Day on September 18th with a special one-day deal, offering their Classic Burger or Classic Cheeseburger with fries for just $8.99. Guests can enjoy this offer for dine-in or To Go. Additionally, Applebee's is featuring upgraded cheeseburger experiences throughout the month, including their viral O-M-Cheese Burger and the new O-M-Cheese-adilla Burger, available on their 2 for $25 menu.

Union Pacific Corporation's CEO, Jim Vena, and CFO, Jennifer Hamann, are scheduled to address the Morgan Stanley 14th Annual Laguna Conference on Wednesday, September 16, 2026, at 12:15 p.m. ET. A live webcast of their presentation will be accessible through the investor relations section of Union Pacific's website, with an audio replay available shortly after. The company, operating in 23 western states, emphasizes its role in connecting communities to the global economy and its commitment to environmentally responsible freight transportation.

HC Wainwright has reaffirmed its "Neutral" rating for Evommune (NYSE:EVMN), while the broader analyst consensus remains a "Moderate Buy" with an average price target of $41.56. Despite shares opening higher, the clinical-stage biotech missed its recent quarterly earnings estimates, reporting a loss of $0.89 per share against an expected $0.68 loss. Insider selling amounting to $655,000 occurred in the last quarter, yet institutional investors like Janus Henderson and Perceptive Advisors have built significant positions in the company.